Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
993 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01186484 | Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer | completed | Phase 1 | 27 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Oct 23, 2017 | clinicaltrials |
| NCT01713387 | A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy | completed | Phase 1 | 38 | Kansai Hepatobiliary Oncology GroupNETWORK | 1 | Oct 9, 2017 | clinicaltrials |
| NCT00960258 | Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors. | completed | Phase 1 | 15 | BayerINDUSTRY | 1 | Sep 27, 2017 | clinicaltrials |
| NCT01881217 | First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors | completed | Phase 1 | 35 | BayerINDUSTRY | 3 | Sep 14, 2017 | clinicaltrials |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy | terminated | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01610479 | A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2017 | clinicaltrials |
| NCT01682473 | A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies | completed | Phase 1 | 20 | Zenyaku Kogyo Co., Ltd.INDUSTRY | 1 | Jul 6, 2017 | clinicaltrials |
| NCT02428036 | A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions | completed | Phase 1 | 6 | Takara Bio Inc.INDUSTRY | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01179295 | Japanese BAY86-9766 Monotherapy Phase I Study | completed | Phase 1 | 12 | BayerINDUSTRY | 1 | Jun 20, 2017 | clinicaltrials |
| NCT01957579 | A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Jun 12, 2017 | clinicaltrials |
| NCT02514603 | A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers | completed | Phase 1 | 12 | Eli Lilly and CompanyINDUSTRY | 1 | May 22, 2017 | clinicaltrials |
| NCT01776411 | Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients | completed | Phase 1 / Phase 2 | 49 | Mundipharma K.K.INDUSTRY | 1 | May 11, 2017 | clinicaltrials |
| NCT01199822 | Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors | completed | Phase 1 | 16 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 14, 2017 | clinicaltrials |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C | terminated | Phase 1 | 12 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Mar 29, 2017 | clinicaltrials |
| NCT01069757 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 16 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01251796 | A Study of ARQ 197 in Combination With Erlotinib | completed | Phase 1 | 9 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01943292 | Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | completed | Phase 1 | 9 | Verastem, Inc.INDUSTRY | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01839604 | A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma | completed | Phase 1 | 58 | AstraZenecaINDUSTRY | 4 | Mar 6, 2017 | clinicaltrials |
| NCT01656265 | Study of ARQ 197 in Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 24 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01935856 | Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis | completed | Phase 1 / Phase 2 | 20 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02192567 | Open Label Study of DS-5573a | terminated | Phase 1 | 19 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02598570 | Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma | completed | Phase 1 | 7 | AbbVieINDUSTRY | 1 | Feb 6, 2017 | clinicaltrials |
| NCT01088464 | Study of IMC-11F8 in Participants With Advanced Solid Tumors | completed | Phase 1 | 15 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02953808 | Phase 1 Study of GSK2315698 in Healthy Japanese Subjects | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 1 | Jan 19, 2017 | clinicaltrials |
| NCT02697552 | Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma | completed | Phase 1 | 13 | HUYABIO International, LLC.INDUSTRY | 1 | Jan 12, 2017 | clinicaltrials |
| NCT00970411 | Study of KRN951 in Patients With Solid Tumors | completed | Phase 1 | 12 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jan 5, 2017 | clinicaltrials |
| NCT01661179 | Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma | completed | Phase 1 / Phase 2 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT00876460 | BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I | completed | Phase 1 | 43 | Boehringer IngelheimINDUSTRY | 1 | Nov 17, 2016 | clinicaltrials |
| NCT01773434 | A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103) | completed | Phase 1 | 46 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 10, 2016 | clinicaltrials |
| NCT01605916 | Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer | completed | Phase 1 | 33 | AstraZenecaINDUSTRY | 1 | Oct 21, 2016 | clinicaltrials |
| NCT01565746 | Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients | completed | Phase 1 | 19 | BayerINDUSTRY | 1 | Oct 17, 2016 | clinicaltrials |
| NCT00280397 | An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors | completed | Phase 1 | 27 | Eisai Inc.INDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT01432886 | A Study of Eribulin Mesylate With Trastuzumab for Advanced or Recurrent Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer | completed | Phase 1 | 12 | Eisai Co., Ltd.INDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02116569 | A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 9 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Sep 26, 2016 | clinicaltrials |
| NCT01213160 | Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient | completed | Phase 1 | 40 | AstraZenecaINDUSTRY | 1 | Jun 29, 2016 | clinicaltrials |
| NCT01227772 | Study of OTSGC-A24 Vaccine in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 23 | National University Hospital, SingaporeOTHER | 3 | Jun 22, 2016 | clinicaltrials |
| NCT01327313 | A Study of EMD525797 in Solid Tumor Patients in Japan | completed | Phase 1 | 27 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | May 13, 2016 | clinicaltrials |
| NCT01949870 | Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study | terminated | Phase 1 | 6 | AstraZenecaINDUSTRY | 1 | May 13, 2016 | clinicaltrials |
| NCT02506803 | Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer. | unknown | Phase 1 | 10 | Wakayama Medical UniversityOTHER | 1 | May 12, 2016 | clinicaltrials |
| NCT01353781 | Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies | completed | Phase 1 | 39 | AstraZenecaINDUSTRY | 1 | Apr 26, 2016 | clinicaltrials |
| NCT00568022 | A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | completed | Phase 1 | 9 | R-PharmINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT00683904 | Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer | completed | Phase 1 | 12 | R-PharmINDUSTRY | 1 | Mar 10, 2016 | clinicaltrials |
| NCT01791374 | Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ | completed | Phase 1 | 21 | AmgenINDUSTRY | 1 | Feb 29, 2016 | clinicaltrials |
| NCT01657214 | Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients(SARMETA) | completed | Phase 1 | 70 | SanofiINDUSTRY | 2 | Feb 17, 2016 | clinicaltrials |
| NCT01929486 | Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer. | unknown | Phase 1 | 58 | Aichi Medical UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01594125 | Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Boehringer IngelheimINDUSTRY | 1 | Feb 12, 2016 | clinicaltrials |
| NCT02154646 | A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body | completed | Phase 1 | 6 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 10, 2016 | clinicaltrials |
| NCT01018784 | A Study of MORAb-009 in Patients With Solid Tumor | completed | Phase 1 | 17 | Eisai Co., Ltd.INDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01588548 | Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma | completed | Phase 1 | 43 | AstraZenecaINDUSTRY | 2 | Nov 4, 2015 | clinicaltrials |
| NCT01293630 | A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors | completed | Phase 1 | 18 | SanofiINDUSTRY | 1 | Oct 30, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials